NCT04129060View on ClinicalTrials.gov

Cholinergic Health After Menopause (CHAMP)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 15, 2020

Primary Completion Date

December 16, 2024

Study Completion Date

December 16, 2024

Conditions
Postmenopausal SymptomsAgingAlzheimer Disease
Interventions
DRUG

Cholinergic antagonist

The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo

Trial Locations (2)

37212

Vanderbilt University Medical Center, Nashville

05401

University of Vermont, Burlington

All Listed Sponsors
collaborator

Vanderbilt University Medical Center

OTHER

lead

University of Vermont

OTHER

NCT04129060 - Cholinergic Health After Menopause (CHAMP) | Biotech Hunter | Biotech Hunter